The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC).
S. S. Ramalingam
Consultant or Advisory Role - Genentech; OSI Pharmaceuticals; Roche
Honoraria - Genentech
D. R. Spigel
Consultant or Advisory Role - Roche
M. Steins
Honoraria - Roche
J. A. Engelman
Consultant or Advisory Role - Genentech
C. Schneider
No relevant relationships to disclose
S. Novello
No relevant relationships to disclose
W. E. Eberhardt
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Novartis; OSI Pharmaceuticals; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Novartis; OSI Pharmaceuticals; Pfizer; Roche
L. Crino
Honoraria - Roche
P. A. Janne
Consultant or Advisory Role - Abbott Laboratories; AstraZeneca (U); Boehringer Ingelheim; Genentech; Pfizer (U); Roche
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - Genzyme
L. Liu
Employment or Leadership Position - Roche
C. M. Brownstein
Employment or Leadership Position - Roche
M. Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Lilly; Merck; Roche